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ABSTRACT
Background
Renal involvement is a serious manifestation of systemic lupus erythematosus (SLE); it may
portend a poor prognosis as it may lead to end-stage renal disease (ESRD). The purpose of this
study was to determine the factors predicting the development of renal involvement and its
progression to ESRD in a multi-ethnic SLE cohort (PROFILE).
Methods and Findings
PROFILE includes SLE patients from five different United States institutions. We examined at
baseline the socioeconomic–demographic, clinical, and genetic variables associated with the
development of renal involvement and its progression to ESRD by univariable and multivariable
Cox proportional hazards regression analyses. Analyses of onset of renal involvement included
only patients with renal involvement after SLE diagnosis (n¼229). Analyses of ESRD included all
patients, regardless of whether renal involvement occurred before, at, or after SLE diagnosis (34
of 438 patients). In addition, we performed a multivariable logistic regression analysis of the
variables associated with the development of renal involvement at any time during the course
of SLE.
In the time-dependent multivariable analysis, patients developing renal involvement were
more likely to have more American College of Rheumatology criteria for SLE, and to be
younger, hypertensive, and of African-American or Hispanic (from Texas) ethnicity. Alternative
regression models were consistent with these results. In addition to greater accrued disease
damage (renal damage excluded), younger age, and Hispanic ethnicity (from Texas),
homozygosity for the valine allele of FccRIIIa (FCGR3A*GG) was a significant predictor of ESRD.
Results from the multivariable logistic regression model that included all cases of renal
involvement were consistent with those from the Cox model.
Conclusions
Fcc receptor genotype is a risk factor for progression of renal disease to ESRD. Since the
frequency distribution of FCGR3A alleles does not vary significantly among the ethnic groups
studied, the additional factors underlying the ethnic disparities in renal disease progression
remain to be elucidated.
The Editors’ Summary of this article follows the references.
PLoS Medicine | www.plosmedicine.org October 2006 | Volume 3 | Issue 10 | e396 1949
PLoS MEDICINEIntroduction
Systemic lupus erythematosus (SLE) is a prototypic
immune complex disease characterized by a variable course
and outcome. Renal involvement, one of the most serious
manifestations, is clinically heterogeneous. Even among
patients with the most severe histological forms of renal
involvement, not all patients develop end-stage renal disease
(ESRD) [1–3]. Compared to White Americans (Caucasians),
other ethnic groups around the world tend to develop renal
disease more frequently and to have worse outcomes [4–12].
Familial aggregation of SLE suggests a genetic component
to disease susceptibility. Numerous studies have now found
genetic associations with individual candidate genes [13–16].
Amongst the most robust candidate genes studied to date,
those encoding HLA-DR, low-afﬁnity Fc receptors for IgG
(FCGR), (C4) complement, IRF5, mannose-binding lectin,
CTLA4, and programmed cell death-1 have shown consistent
association with SLE. Other candidate genes include certain
cytokines and the Fas/FasL system. Of particular interest to
the development of renal disease in patients with SLE is the
reported association of renal disease with the low binding
allele of FCGR3A (the FCGR3A*T allele), a ﬁnding supported
by a recent meta-analysis [17,18]. Both global SLE phenotype
and renal disease in patients with IgG2 anti-C1q autoanti-
bodies have been associated with alleles of FCGR2A [19].
Recently, variation at the FCGR3B locus has also been related
to renal disease in patients with SLE [20], making these three
FCGR genes strong candidates for association with end organ
damage and ESRD.
We have previously reported on a multi-ethnic, multi-
center cohort of SLE patients, named PROFILE [21]. This
cohort was constituted in 1998 by combining the existing
cohorts at Northwestern University, Johns Hopkins Univer-
sity, the University of Alabama at Birmingham, the University
of Texas Health Science Center at Houston, and the
University of Puerto Rico Medical Sciences Campus (UPR)
[22]. The underlying hypothesis was that the patients’ genetic
proﬁle might allow for the prediction of their disease
phenotype, hence the name PROFILE. We perform time-
dependent analyses to determine the pace at which renal
involvement and ESRD occurred in this SLE cohort. These
data provide insight into the pathogenesis of these events and
shed light on potential preventive strategies.
Methods
Institutional review board approval to constitute this
cohort and to follow these patients over time was obtained
at each participating institution in accordance with the
Declaration of Helsinki.
As previously described [21], PROFILE is a multi-institu-
tional cohort of SLE patients. PROFILE patients are those
from the individual cohorts who meet the American College
of Rheumatology (ACR) revised and updated criteria [23,24],
are 16 y of age or older, and have disease duration  10 y at
the time they enter this cohort. They are also of deﬁned
ethnicity (Hispanic of Mexican ancestry [residing and
enrolled in Texas, hence Texan Hispanics], Hispanic of
Puerto Rican ancestry [residing and enrolled in Puerto Rico,
hence Puerto Rican Hispanics], African-American, and White
Americans), having reported all four grandparents to be of
the same ethnic background. The patients are geographically
distributed as follows: 132 patients from Northwestern
University, 373 from Johns Hopkins University, 240 from
University of Alabama at Birmingham, 171 from University of
Texas Health Science Center at Houston, and 92 from UPR.
The PROFILE database consists of those variables common to
the individual cohorts that were identiﬁed after carefully
mapping the different cohorts’ databases [21]. The variables
for the current analyses include both socioeconomic–demo-
graphic elements (age, gender, education, employment,
marital status, and smoking) and clinical elements (disease
duration, the number of ACR criteria at entry into the cohort
[renal criterion excluded], renal involvement, ESRD, damage
as assessed by the Systemic Lupus International Collaborating
Clinics Damage Index [SDI], and medication intake [cyclo-
phosphamide, azathioprine, mycophenolate mofetil, and
glucocorticoids] [25,26]). For the purpose of these analyses,
however, the SDI renal domain items were excluded.
Comorbidities (diabetes [intake of oral hypoglycemic agents
or insulin] and hypertension [recording of three abnormal
readings or use of antihypertensive medications]) and the use
of cyclophosphamide were also included.
Time of diagnosis was deﬁned as the date at which a patient
met four ACR criteria; therefore, renal involvement could
have occurred prior to SLE diagnosis, at diagnosis, or after
diagnosis. Disease duration was deﬁned as the time between
diagnosis and enrollment into the PROFILE cohort. Renal
involvement was deﬁned as present at the time patients met
the ACR renal disorder criterion [23] or had biopsy-proven
World Health Organization Class II–V lupus nephritis (for
those in whom these data were available). ESRD was deﬁned
as the need for dialysis or transplantation.
From the genetic domain, selected HLA-DRB1 (HLA-
DRB1*01, HLA-DRB1*0301, and HLA-DRB1*08), HLA-DQB1
(HLA-DQB1*0201 and HLA-DQB1*0602), HLA-DQA1 (HLA-
DQA1*0501), FCGR2A, FCGR3A, and FCGR3B alleles were
included. Genomic DNA was extracted using the PureGene
kit (Gentra Systems, Minneapolis, Minnesota, United States)
following the manufacturer’s recommendations. HLA-DRB1,
HLA-DQB1, and HLA-DQA1 were genotyped as we have
previously described [22]. FCGR2A, FCGR3A, and FCGR3B
were genotyped as previously described and by Pyrosequenc-
ing (Biotage, Charlottesville, Virginia, United States) using
gene-speciﬁc primers [27]. The distributions of selected HLA-
DR, HLA-DQ, and FCGR alleles by ethnic group are included
in Table S1.
The common variables from the individual databases were
pooled to constitute one single database [21]. Descriptive
statistical tests (Chi-square for proportions and Student’s tests
for means) were used to compare variables from the different
domains for incident cases of renal involvement and for
incident and prevalent cases taken together versus non-cases
(prevalent cases, deﬁned as those occurring prior to SLE
diagnosis). Descriptive comparisons were also made between
all patients whose renal involvement (prevalent and incident
cases) had evolved into ESRD and those whose renal involve-
ment had not. The effects of FCGR3A genotypes on the
occurrence of ESRD were examined by Kaplan-Meier survival
analysis. Variables with p , 0.10 in the univariable analyses
and those felt to be clinically relevant regardless of their level
of signiﬁcance (e.g., hypertension) were entered into Cox
proportional hazards regression models. The dependent
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Renal Disease and ESRD in PROFILE Cohortvariable was time to renal involvement in one model and time
to ESRD in the other. In the case of renal involvement only
those patients who developed it after entering the cohort were
included in the model. Gender, age, and ethnicity were
entered in both models. Occupation was excluded in the
ESRD model since changes in patients’ occupation status may
result from ESRD rather than predict its occurrence. In two
alternative models for renal involvement, treatment center
rather than ethnicity was entered in one, and both treatment
center and ethnicity were examined in the other; UPR
patients were excluded in this analysis since all UPR patients
have the same ethnicity. Finally, in another model all patients
who developed renal involvement regardless of when it
occurred were included; given that many of the independent
variables were ascertained at baseline and not at diagnosis, a
multivariable logistic regression rather than a Cox multi-
variable analysis of time to the event was performed.
Histopathological data were not included in the ESRD
regression given that this information was not available in
nearly 45% of all patients. All analyses were done using SAS
software, version 8.1 (SAS Institute, Cary, North Carolina,
United States). Figure 1 depicts the ﬂow of PROFILE patients
into the time-dependent analyses described.
Results
Renal Involvement
At the time of analysis, 1,008 patients constituted the
PROFILE cohort, 438 of whom had developed renal
involvement (Figure 1A). Of these 438 patients, 209 had
developed renal involvement prior to or at diagnosis
(prevalent cases). At baseline, the 229 incident cases (those
who developed renal involvement after SLE diagnosis) were
younger (36.1 versus 39.7 y, p , 0.001) and more likely to be
unemployed (48.9% versus 35.6%, p , 0.001), to have had
fewer years of formal education (13.0 versus 13.9 y, p ¼
0.001), to have a greater number of ACR criteria (excluding
the renal criterion) (7.0 versus 5.5, p , 0.001), to have had a
longer disease duration (4.8 versus 2.7 y, p , 0.001), and to
be hypertensive (45.7% versus 26.3%, p , 0.001) compared
to the ones who had not developed renal involvement.
African-Americans (105 of 237 patients, 44%) and Texan
Hispanics (38 of 83 patients, 45%) were more likely to have
developed renal involvement than the White Americans (73
of 392 patients, 18%) and Puerto Rican Hispanics (eight of
82 patients, 9%). These data are depicted in Table 1. The
distribution of HLA-DRB1, HLA-DQA1, HLA-DQB1, and
FCGR alleles were comparable for those patients who had
developed and those who had not developed renal involve-
ment (data not shown). Similar comparisons were carried
out for all incident and prevalent cases together. These
analyses were consistent with the data presented in Table 1
with the exception of smoking, which appeared to be
somewhat less frequent among those who developed versus
those who did not develop renal involvement (data not
shown). In terms of the HLA-DR, HLA-DQ, and FCGR alleles,
the data were also comparable between those with and
without renal involvement with the exception of HLA-
DRB1*1503, which associates with African-American ethnic-
ity and which was found to be more frequent among those
with renal involvement (13.5%) than among those without it
(9.9%) (p , 0.001).
End-Stage Renal Disease
As shown in Figure 1B, 34 patients, from a total of 438
patients with renal involvement (incident and prevalent
cases), had developed ESRD at the time of these analyses.
Renal biopsies were not required for entry into the PROFILE
database, but none of these patients had a lupus-scleroderma
or other overlap syndrome to which ESRD could have been
Figure 1. Flow Diagram of PROFILE Cohort Patients Included in Analyses
(A) Renal involvement (double-lined boxes).
(B) ESRD (triple-lined box).
DOI: 10.1371/journal.pmed.0030396.g001
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Renal Disease and ESRD in PROFILE Cohortattributed. Very few of our patients received nonsteroidal
anti-inﬂammatory drugs once renal involvement occurred;
thus, nonsteroidal anti-inﬂammatory drug use as a principal
contributing factor for the evolution into ESRD was
considered highly unlikely. As shown in Table 2, patients
whose condition evolved into ESRD were younger (31.8 versus
36.5 y, p ¼ 0.0364) and more likely to be unemployed (75.8%
versus 43.1%, p , 0.001), to have had fewer years of formal
education (11.9 versus 13.2 y, p ¼ 0.0218), to have had a
shorter disease duration at entry into the cohort (1.0 versus
4.8 y, p¼0.003), and to have accrued more damage (excluding
all renal domain items) (2.18 versus 1.43, p ¼ 0.0280) at entry
into the cohort. Within the different ethnic groups, ESRD was
more likely to occur among Texan Hispanics affected with
renal involvement (10 of 54 patients, 15%) than among
patients in the other ethnic groups (24 of 374 patients, 6%, p
¼ 0.0233). Hypertension, diabetes, and the use of cyclo-
phosphamide, azathioprine, and mycophenolate mofetil
occurred with comparable frequency in those patients who
developed and those who did not develop ESRD. When these
immunosuppressants were considered as a group, however,
patients whose renal disease evolved into ESRD were more
likely to have been treated with them than those whose
disease did not, but the highest dose of glucocorticoids (as
prednisone equivalent) was comparable in both groups.
There was an overrepresentation of FCGR3A*GG among
those patients who developed ESRD (21.9%) versus those who
did not develop it (7.5%) (p ¼ 0.0175), but the distribution of
the other FCGR2A and FCGR3B alleles and of HLA-DRB1,
HLA-DQ1, and HLA-DQB1 alleles were comparable for those
patients reaching and not reaching ESRD (data not shown).
Figure 2 depicts the Kaplan-Meier survival curve of the
genotypic effects of FCGR3A*GG versus FCGR3A*TT/GT on
ESRD development.
Multivariable Analyses: Time to Renal Involvement
The results of the Cox proportional hazard regression are
shown in Table 3. Variables independently associated with
time to the occurrence of renal involvement were younger
age (hazard ratio [HR] ¼ 0.975; 95% conﬁdence interval [CI]
0.962–0.988), African-American (HR ¼ 3.233; 95% CI 2.131–
4.906) and Texan Hispanic (HR ¼ 2.806; 95% CI 1.556–5.601)
ethnicities, and the number of ACR criteria (renal criterion
excluded) (HR¼1.415; 95% CI 1.286–1.558). Male gender and
hypertension were also associated with this outcome (HR ¼
1.647 and 1.453, respectively), but statistical signiﬁcance was
not reached.
To consider possible treatment center effects, we included
both treatment center and ethnicity in alternative models of
time to renal involvement. Given that all patients at UPR are
from the same ethnic group, these patients were excluded in
these analyses. The same variables were retained in those
alternative models, therefore excluding a treatment center
effect as a contributing variable to the development of renal
involvement.
Factors Associated with the Occurrence of Renal
Involvement
Table 4 depicts the variables independently associated with
the occurrence of renal involvement, regardless of the time
when it occurred (n ¼ 438). These variables were African-
American ethnicity (odds ratio [OR] ¼ 3.311; 95% CI 2.366–
4.634), male gender (OR ¼ 2.703; 95% CI 1.546–4.717),
number of ACR criteria at cohort entry (OR ¼ 1.491; 95%
CI 1.321–1.684), disease duration (OR¼1.073; 95% CI 1.035–
1.111), and hypertension (OR ¼ 2.595; 95% CI 1.823–3.695).
Older age (OR¼0.963; 95% CI 0.950–0.976), education (OR¼
0.914; 95% CI 0.866–0.965), and smoking (OR¼0.406; 95% CI
0.259–0.636) were negatively associated with the occurrence
of renal involvement.
Table 1. Baseline Socioeconomic–Demographic and Clinical Features of PROFILE Patients as a Function of Renal Involvement (Incident
Cases)
Variable Subcategory Renal Involvement p-Value
a
Yes (n ¼ 229) No (n ¼ 570)
Age (y), mean (SD) 36.1 (12.5) 39.7 (12.5) 0.0004
Gender (% women) 92.6 93.6
Ethnicity (%) Texan Hispanic 16.6 7.8
Puerto Rican Hispanic 3.5 12.8
African-American 45.9 22.8 ,0.001
White American 31.9 55.2
Other 2.2 1.4
Employment (% working) 51.1 64.4 ,0.001
Education (y), mean (SD) 13.0 (2.9) 13.9 (3.0) ,0.001
Marital status (% married) 37.7 45.3 0.0508
Smoking (%) 16.2 20.0
ACR criteria number, mean (SD) 7.0 (1.6) 5.5 (1.3) ,0.001
Disease duration
b (y), mean (SD) 4.8 (5.7) 2.7 (3.5) ,0.001
SDI
c, mean (SD) 1.39 (1.87) 1.06 (1.85)
Hypertension (%) 45.7 26.3 ,0.001
Diabetes (%) 9.0 6.4
aOnly p   0.10 is shown.
bFrom diagnosis to baseline.
cRenal domain items excluded.
SD, standard deviation.
DOI: 10.1371/journal.pmed.0030396.t001
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Table 5 shows the variables independently associated with
time to the occurrence of ESRD among all those PROFILE
patients who had developed renal involvement (prevalent and
incident cases). These variables were younger age (HR¼0.958;
95% CI 0.919–0.998), Texan Hispanic ethnicity (HR ¼ 6.771;
95% CI 1.119–40.958), and the presence of FCGR3A*GG (HR
¼ 5.142; 95% CI 1.193–22.173). Polymorphisms of FCGR2A
and FCGR3B were not retained in this model.
Discussion
We have previously shown that renal involvement is more
frequent among SLE patients of African-American and Texan
Hispanic (primarily Mexican) ancestry [28]. We have now
shown that, in addition, the pace at which renal involvement
occurs is also faster in these patients as compared to both
White Americans and Puerto Rican Hispanics. Furthermore,
we have shown, to our knowledge for the ﬁrst time, that a
polymorphism of FCGR3A (FCGR3A*GG) predisposes lupus
patients with renal involvement to the occurrence of ESRD
over and above other socioeconomic–demographic and
clinical variables included in the model.
In addition to African-American and Texan Hispanic
(Mexican) ancestry, younger age, hypertension, and having a
greater number of ACR criteria (renal criterion excluded)
were associated with a shorter time to the occurrence of renal
involvement. We did ﬁnd association of the FCGR3A*T allele
with the lupus phenotype in White American patients in our
cohort relative to a geographically and ethnically matched
population (OR ¼ 1.24, 95%CI: 1.01–1.52; p ¼ 0.024).
Interestingly, we did not ﬁnd an association with renal
involvement as opposed to non-renal lupus. Based on the
meta-analyses of Karassa et al. [17] and Seligman et al. [18],
this absence may represent a relative lack of statistical power
for this effect, which has an estimated OR of 1.2. Similarly,
the absence of an association of HLA-DRB1, HLA-DQB1, and
HLA-DQA1 alleles with renal involvement in our cohort may
represent a power issue for HLA-DRB1*15 (HLA-DR2) and
other alleles previously reported to be associated with lupus
nephritis [17,29]. Given the exploratory nature of our
analyses, however, a formal power calculation was not done
a priori.
The ﬁnding that the FCGR3A*T allele is associated with the
global lupus phenotype but that homozygosity for the
FCGR3A*G allele is a risk factor for ESRD suggests that
Table 2. Baseline Socioeconomic–Demographic and Clinical Features of PROFILE Patients with Renal Involvement (Incident and
Prevalent Cases) as a Function of the Occurrence of ESRD
Variable Subcategory ESRD p-Value
a
Yes (n ¼ 34) No (n ¼ 404)
Age (y), mean (SD) 31.8 (10.6) 36.5 (12.6) 0.0364
Gender (% women) 88.3 88.3
Ethnicity Texan Hispanic 29.4 13.4
Puerto Rican Hispanic 0 4.5
African-American 44.1 47.0 0.0233
White American 26.5 33.2
Other 0 1.9
Employment (% working) 24.2 56.9 ,0.001
Education (y), mean (SD) 11.9 (2.8) 13.2 (2.9) 0.0218
Marital status (% married) 35.4 38.4
Smoking (%) 17.7 14.2
ACR criteria number, mean (SD) 6.7 (1.8) 6.6 (1.6)
Disease duration
b (y), mean (SD) 1.0 (1.1) 4.8 (6.1) ,0.001
Hypertension (%) 55.9 48.5
Diabetes (%) 9.4 10.9
Cyclophosphamide use (%) 20.6 16.3
Azathioprine use (%) 35.3 34.9
Mycophenolate mofetil use (%) 14.7 16.6
Cyclophosphamide or azathioprine or mycophenolate mofetil use (%) 85.3 61.1 0.0019
Highest dose of prednisone (mg/d), mean (SD) 65.3 (46.3) 55.1 (33.8)
SDI
c, mean (SD) 2.18 (2.04) 1.43 (1.82) 0.0280
aOnly p   0.10 is shown.
bFrom diagnosis to baseline; the mean disease duration at the time these patients developed ESRD was 4.5 y.
cRenal domain items excluded.
SD, standard deviation.
DOI: 10.1371/journal.pmed.0030396.t002
Figure 2. Kaplan-Meier Survival Curve for the Development of ESRD in
Patients with FCGR3A*GG and FCGR3A*TT/GT
DOI: 10.1371/journal.pmed.0030396.g002
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Renal Disease and ESRD in PROFILE Cohortgenetic factors inﬂuencing the tempo and severity of end
organ disease progression may be distinct from those
determining initial disease susceptibility. Indeed, work in
mouse models suggests that end organ damage may be
regulated differently from disease susceptibility [30]. It is
likely that the low binding allele of FCGR3A predisposes to
the global SLE phenotype by virtue of its relative lowered
capacity to handle immune complexes. In contrast, once
organ damage is initiated, the higher binding allele of
FCGR3A may cause more activation and greater local damage,
consistent with our observed association of ESRD with
FCGR3A*GG.
Given that most variables included in the multivariable
analyses were from the baseline visit, we felt that a Cox
proportional hazard multivariable analysis including only
patients who developed renal involvement after diagnosis
(incident cases) was the most appropriate to examine our
data. Nonetheless, when all patients who developed renal
involvement were included in multivariable analyses, the
results were consistent with the ones presented in Table 3.
Interestingly, male gender and hypertension became signiﬁ-
cant, whereas smoking was negatively associated with the
occurrence of renal involvement, perhaps suggesting that our
smokers were overall healthier than the non-smokers.
In the analysis of time to the occurrence of ESRD, we
included all patients who developed renal involvement
regardless of the time at which it was ﬁrst detected (incident
and prevalent cases). Texan Hispanic patients (Mexican
ancestry) were more likely to develop ESRD than patients
in the other ethnic groups, as demonstrated in both the
univariable and multivariable analyses. We not only found
that FCGR3A*GG was overrepresented in those patients who
went on to develop ESRD, but also that patients with this
genotype were also more likely to experience a shorter time
to the occurrence of ESRD (as compared to those patients
with either FCGR3A*GT or FCGR3A*TT). Differences in the
distribution of FCGR3A alleles across the ethnic groups were
not the explanation for these ﬁndings, as both we and others
have found the allele frequencies comparable across His-
panics, African-Americans, and White Americans (Table S2).
Younger age was a signiﬁcant factor in these analyses, but
education was not. Nevertheless, given that ethnicity is not
merely a biological construct but one that also encompasses
ancestry, geography, history, values, culture, and language,
the role of socioeconomic factors in the evolution to ESRD
cannot be easily dismissed.
Our study has several limitations. First, it includes SLE
patients recruited at academic health centers, and, thus, they
may not be representative of the overall lupus population;
this may make our data less generalizable than if our patients
have been recruited from the wider community. Second,
because different disease activity indices such as the SLEDAI
(Systemic Lupus Erythematosus Disease Activity Index)
[31,32] and the SLAM-R (Systemic Lupus Activity Measure–
Revised) [33,34] cannot be pooled, we were unable to assess
the relationship of ongoing non-clinical renal disease activity
with the occurrence of renal involvement [28]. Likewise, we
were unable to include histopathological and autoantibody
data, such as anti-dsDNA antibodies, given that they were
unavailable in a sizable proportion of patients (about 45% in
the case of histopathology) or that they were not obtained at
the same time in the course of the disease and were not
assayed in a single laboratory using the same technique in all
cohort patients (in the case of autoantibodies). Although our
patients were not treated using exactly the same protocol, the
proportion of patients who received individual immunosup-
pressants and the dose of glucocorticoids used were com-
parable between those whose renal disease evolved into ESRD
and those whose disease did not. However, immunosuppres-
sants as a group were more commonly used among those
whose condition evolved into ESRD than those whose
condition did not. Although it would have been preferable
if all patients in this combined cohort had been treated using
Table 3. Baseline Predictors of Time to Renal Involvement in PROFILE Patients by Cox Multivariable Proportional Hazards Regression
Analysis
Variable Subcategory HR 95% CI p-Value
Age 0.975 0.962–0.988 ,0.001
Gender (male) 1.647 0.936–2.899 0.0835
Ethnicity
a African-American 3.233 2.131–4.906 ,0.001
Texan Hispanic 2.806 1.556–5.061 ,0.001
ACR criteria number 1.415 1.286–1.558 ,0.001
Hypertension 1.453 0.956–2.207 0.0802
Values adjusted for education, marital status, occupation, insurance, hypertension, diabetes, and damage.
aWhite American is the reference group.
DOI: 10.1371/journal.pmed.0030396.t003
Table 4. Variables Independently Associated with the Occur-
rence of Renal Involvement at Any Time during the Course of
SLE in PROFILE Patients
Variable OR 95% CI p-Value
Age 0.963 0.950–0.976 ,0.001
Gender (male) 2.703 1.546–4.717 ,0.001
African-American ethnicity 3.311 2.366–4.634 ,0.001
Education 0.914 0.866–0.965 0.011
Smoking 0.406 0.259–0.636 ,0.001
ACR criteria number 1.491 1.321–1.684 ,0.001
Total disease duration
a 1.073 1.035–1.111 ,0.001
Hypertension 2.595 1.823–3.695 ,0.001
Values adjusted for marital status, occupation, damage, and diabetes.
aFrom diagnosis to last visit or to the occurrence of renal involvement.
DOI: 10.1371/journal.pmed.0030396.t004
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Renal Disease and ESRD in PROFILE Cohorta standardized protocol, we do not think that progression to
ESRD resulted primarily from differences in treatment. The
roles of access to care, compliance with treatment, and family
history of renal disease, while potentially important in the
evolution from renal involvement to ESRD [4,35–38], were
not examined in a standard manner, and thus such data were
not available for pooled analyses.
Despite these limitations, our data are quite relevant to
clinicians caring for patients from ethnic minorities, partic-
ularly young Hispanics (primarily of Mexican and Central
American ancestry) and African-Americans, who tend to have
a lower socioeconomic status in the US than the White
American majority. Whether, like African-Americans, His-
panic patients of Mexican ancestry are less likely to respond
to conventional treatment with pulse cyclophosphamide once
renal involvement ensues deserves further examination [39].
Furthermore, our study provides insightful information as to
the possible genetic basis underlying the progression to ESRD
in lupus patients with renal involvement. As new treatments
are developed for lupus nephritis, patients from these and
other minority groups should be included to ensure that data
generated in these trials are applicable to the SLE patients of
various ancestral backgrounds.
Supporting Information
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Editors’ Summary
Background. Systemic lupus erythematosis (SLE, commonly known as
‘‘lupus’’) is an illness of many manifestations that appear to result from
the immune system attacking components of the body’s own cells. One
of the unfortunate effects of SLE is kidney damage, which can, in a
minority of patients, progress to kidney failure (formally called ‘‘end-
stage renal disease,’’ or ESRD). Compared to White Americans, other
ethnic groups tend to develop renal complications of lupus more often
and with worse outcomes.
Why Was This Study Done? It is unclear why some people with lupus
develop kidney problems. The purpose of this US-based study was to
confirm the factors that increase the risk of kidney damage and kidney
failure, particularly in racial and ethnic minority patients, and to
determine which of these factors accelerate the pace of kidney disease.
Knowing these risk factors could allow the development and targeting of
interventions, such as screening tests and preventive treatments, to
prevent long-term loss of kidney function in patients with lupus.
What Did the Researchers Do and Find? The researchers measured a
number of factors in a multi-ethnic group of 1,008 patients with lupus,
almost half of whom had some degree of kidney involvement. They
found that those who developed kidney damage after being diagnosed
with lupus tended to be younger, to have had lupus for a longer time,
and to have experienced more effects of lupus in general than those
who did not have kidney involvement. Those who developed kidney
problems were also more likely to have been unemployed, to have had
fewer years of formal education, and to have had high blood pressure
before developing kidney involvement. African-American and Texan
Hispanic individuals with lupus were more likely to develop kidney
involvement, and tended to develop it more rapidly, than White
Americans or Puerto Rican Hispanic ethnicity. Actual kidney failure
(ESRD requiring dialysis or kidney transplantation) was more likely to
occur among Texan Hispanics with kidney involvement than in the other
ethnic groups. Diabetes and high blood pressure were not found to
predict ESRD, but people with a particular variant of a protein that helps
antibodies bind to cells (know as Fc-gamma receptor IIIa, or FccRIIIa)
were found to be more likely to develop ESRD, and to develop it more
quickly.
What Do These Findings Mean? These results suggest that the
emergence and progression of kidney disease in patients with lupus
depends on medical, genetic, and socioeconomic factors. Because no
single test or intervention can be expected to address all of these factors,
those treating patients with lupus must remain aware of the complexity
of their patients lives at a variety of levels. In particular, ethnic disparities
in the risk of serious kidney disease remain to be addressed.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0030396.
  MedlinePlus page on lupus
  Lupus Foundation of America
  American College of Rheumatology pages on lupus
  Wikipedia entry on lupus (note: Wikipedia is a free Internet
encyclopedia that anyone can edit)
PLoS Medicine | www.plosmedicine.org October 2006 | Volume 3 | Issue 10 | e396 1956
Renal Disease and ESRD in PROFILE Cohort